Podoplanin promotes tumor growth, platelet aggregation, and venous thrombosis in murine models of ovarian cancer

Abstract

BackgroundPodoplanin (PDPN) is a sialylated membrane glycoprotein that binds to C‐type lectin‐like receptor 2 on platelets resulting in platelet activation. PDPN is expressed on lymphatic endothelial cells, perivascular fibroblasts/pericytes, cancer cells, cancer‐associated fibroblasts, and tumor stromal cells. PDPN's expression on malignant epithelial cells plays a role in metastasis. Furthermore, the expression of PDPN in brain tumors (high‐grade gliomas) was found to correlate with an increased risk of venous thrombosis. ObjectiveWe examined the expression of PDPN and its role in tumor progression and venous thrombosis in ovarian cancer. MethodsWe used mouse models of ovarian cancer and venous thrombosis. ResultsOvarian cancer cells express PDPN and release PDPN‐rich extracellular vesicles (EVs), and cisplatin and topotecan (chemotherapies commonly used in ovarian cancer) increase the expression of podoplanin in cancer cells. The expression of PDPN in ovarian cancer cells promotes tumor growth in a murine model of ovarian cancer and that knockdown of PDPN gene expression results in smaller primary tumors. Both PDPN‐expressing ovarian cancer cells and their EVs cause platelet aggregation. In a mouse model of venous thrombosis, PDPN‐expressing EVs released from HeyA8 ovarian cancer cells produce more frequent thrombosis than PDPN‐negative EVs derived from PDPN‐knockdown HeyA8 cells. Blood clots induced by PDPN‐positive EVs contain more platelets than those in blood clots induced by PDPN‐negative EVs. ConclusionsIn summary, our findings demonstrate that the expression of PDPN by ovarian cancer cells promotes tumor growth and venous thrombosis in mice.